

AMENDMENTS TO THE CLAIMS

This listing of claims -- which merely adds one new claim, claim 38 -- will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1. (Previously presented): An endometriosis or infertility treating pharmaceutical composition comprising:

- (i) a therapeutically effective amount of a β -adrenergic agonist, and
- (ii) a pharmaceutically acceptable bioadhesive carrier.

C5
Claim 2. (Previously presented): The composition of claim 1 wherein the β -adrenergic agonist is terbutaline.

Claim 3. (Previously presented): The composition of claim 2 wherein the bioadhesive carrier is a cross-linked water insoluble but water swellable polycarboxylic acid polymer.

Claim 4. (Previously presented): The composition of claim 3, wherein the concentration of terbutaline is about 0.1% to about 0.4% weight/weight.

Claim 5. (Previously presented): The composition of claim 4, wherein the polymer is polycarbophil.

Claim 6. (Previously presented): An endometriosis or infertility treating pharmaceutical composition comprising a therapeutically effective amount of a β -adrenergic agonist.

Claim 7. (Previously presented): The composition of claim 6, wherein the β -adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage that delivers about 1 mg. to about 8 mg. of terbutaline.

Claim 8. (Previously presented): The composition of claim 7 wherein the composition further comprises a bioadhesive, water insoluble but water swellable, cross-linked polycarboxylic acid polymer.

Claim 9. (Previously presented): The composition of claim 8, wherein the polymer is polycarbophil.

Claim 10. (Previously presented): The composition of claim 9 formulated to be administered in a dosage that delivers about 2 mg to about 4 mg of terbutaline.

Claims 11-12. (Cancelled)

C5
com.
Claim 13. (Previously presented): A method of treating endometriosis or infertility, or of improving fertility, comprising administering a therapeutically effective amount of a composition comprising a β -adrenergic agonist and a pharmaceutically acceptable bioadhesive carrier locally to the vaginal mucosa of a patient in need thereof.

Claim 14. (Previously presented): The method of claim 13, wherein the β -adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage that delivers about 1 mg. to about 8 mg. of terbutaline.

Claim 15. (Previously presented): The method of claim 14, wherein the composition is administered in a dosage that delivers about 2 mg to about 4 mg of terbutaline.

Claim 16. (Previously presented): A method of treating endometriosis or infertility, or of improving fertility, comprising administering a therapeutically effective amount of a composition comprising a β -adrenergic agonist and a pharmaceutically acceptable bioadhesive carrier locally to the vaginal mucosa of a patient in need thereof, while avoiding detrimental blood levels of said a β -adrenergic agonist.

Claim 17. (Previously presented): The method of claim 16 wherein the β -adrenergic agonist is terbutaline.

Claim 18. (Previously presented): The method of claim 17 wherein the bioadhesive carrier comprises a cross-linked water insoluble but water swellable polycarboxylic acid polymer.

Claim 19. (Previously presented): The method of claim 18, wherein the polymer is polycarbophil.

Claim 20. (Previously presented): The method of claim 15, wherein the composition is administered every 12 to 96 hours.

Claim 21. (Previously presented): The method of claim 15, wherein the composition is administered twice weekly.

Claim 22. (Previously presented): The method of claim 15, wherein the composition is administered in the form of a tablet.

15
com.
Claims 23-35. (Cancelled)

Claim 36. (Previously presented): A pharmaceutical composition for treating endometriosis comprising:

- (i) terbutaline at a concentration of about 0.1% to about 0.4% weight/weight;
- and
- (ii) polycarbophil.

Claim 37. (Previously presented): A pharmaceutical composition for treating infertility or improving fertility comprising:

- (i) terbutaline at a concentration of about 0.1% to about 0.4% weight/weight;
- and
- (ii) polycarbophil.

C^b
Claim 38. (New): The method of claim 15, wherein the composition is administered in the form of a gel or cream.